MY142094A - 5-membered heterocycles, preparation and application thereof as medicaments - Google Patents

5-membered heterocycles, preparation and application thereof as medicaments

Info

Publication number
MY142094A
MY142094A MYPI20021232A MYPI20021232A MY142094A MY 142094 A MY142094 A MY 142094A MY PI20021232 A MYPI20021232 A MY PI20021232A MY PI20021232 A MYPI20021232 A MY PI20021232A MY 142094 A MY142094 A MY 142094A
Authority
MY
Malaysia
Prior art keywords
inhibition
disease
medicaments
preparation
application
Prior art date
Application number
MYPI20021232A
Inventor
Harnett Jeremiah
Bigg Dennis
Liberatore Anne-Marie
Rolland Alain
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0104943A external-priority patent/FR2823208B1/en
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MY142094A publication Critical patent/MY142094A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

THE INVENTION RELATES TO DERIVATIVES OF THIAZOLES, OXAZOLES OR IMIDAZOLES HAVING AT LEAST ONE OF THE FOLLOWING PHARMACOLOGICAL ACTIVITIES: - INHIBITION OF MONOAMINE OXIDASES (MAO'S) - INHIBITION OF LIPIDIC PEROXIDATION - MODULATION OF SODIUM CHANNELS. THESE COMPOUNDS INCLUDE FOR EXAMPLE: - 2,6-DITERT-BUTYL-4-{ 2-[2-(METHYLAMINO )ETHYL]-1 ,3-THIAZOL-4-YL } PHENOL; AND - 4-METHYLPENTYL 2-[4-(1, 1'-BIPHENYL-4-YL)-1H-IMIDAZOL-2-YL]ETHYLCARBAMATE. AS A RESULT OF THEIR PHARMACOLOGICAL PROPERTIES, SAID COMPOUNDS CAN IN PARTICULAR BE USED TO TREAT ONE OF THE FOLLOWING DISORDERS OR DISEASES: PARKINSON'S DISEASE, SENILE DEMENTIA, ALZHEIMER'S DISEASE, HUNTINGTON'S CHOREA, AMYOTROPHIC LATERAL SCLEROSIS, SCHIZOPHRENIA, DEPRESSIONS, PSYCHOSES, MIGRAINE OR PAINS AND IN PARTICULAR NEUROPATHIC PAINS.
MYPI20021232A 2001-04-10 2002-04-05 5-membered heterocycles, preparation and application thereof as medicaments MY142094A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104943A FR2823208B1 (en) 2001-04-10 2001-04-10 5-CHAIN CHAIN HETEROCYCLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
FR0201811 2002-02-14

Publications (1)

Publication Number Publication Date
MY142094A true MY142094A (en) 2010-09-15

Family

ID=26212970

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20021232A MY142094A (en) 2001-04-10 2002-04-05 5-membered heterocycles, preparation and application thereof as medicaments

Country Status (23)

Country Link
EP (1) EP1379514B1 (en)
JP (1) JP4422964B2 (en)
KR (1) KR100865809B1 (en)
CN (1) CN1284777C (en)
AR (1) AR036329A1 (en)
AU (1) AU2002307980B2 (en)
BR (2) BRPI0208703B1 (en)
CA (1) CA2443403C (en)
CZ (1) CZ304550B6 (en)
DE (1) DE60232959D1 (en)
ES (1) ES2328467T3 (en)
HK (1) HK1070055A1 (en)
HU (1) HU228192B1 (en)
IL (2) IL158121A0 (en)
IS (1) IS2724B (en)
MX (1) MXPA03009194A (en)
MY (1) MY142094A (en)
NO (1) NO326051B1 (en)
NZ (1) NZ528645A (en)
PL (1) PL211939B1 (en)
RU (1) RU2288224C2 (en)
TW (1) TWI248438B (en)
WO (1) WO2002083656A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en) 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
WO2003048140A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
TW200500362A (en) * 2003-04-09 2005-01-01 Japan Tobacco Inc 5-membered heteroaromatic ring compound and pharmaceutical use thereof
DE60307049T2 (en) * 2003-04-25 2007-02-08 Neuro3D Use of piperazine phenothiazine derivatives for the manufacture of a medicament having neuroprotective and / or neurotropic effects on the CNS and / or PNS
FR2888116A1 (en) * 2005-07-08 2007-01-12 Sod Conseils Rech Applic THIAZOLE DERIVATIVES FOR TREATING DYSKINESIES
EP1806819A1 (en) * 2006-01-05 2007-07-11 Constructions Electroniques + Telecommunications, en abrégé "C.E.+T" Backup power system
TW200848417A (en) * 2007-02-22 2008-12-16 Organon Nv Indole derivatives
EP2771335A2 (en) * 2011-10-26 2014-09-03 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
CN113831360A (en) * 2021-09-10 2021-12-24 中钢集团南京新材料研究院有限公司 Method for synthesizing 1-carbazole-boronic acid pinacol ester through amide ortho-oriented boronation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326770A (en) 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
AU4368996A (en) * 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US5969146A (en) * 1995-10-11 1999-10-19 Synthelabo Oxazolidin-2-one derivatives, preparation method therefor and therapeutical use thereof
EP0946587A2 (en) * 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
FR2764889B1 (en) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ID24564A (en) * 1997-10-06 2000-07-27 Lilly Co Eli NEW COMPOUNDS USING AS NERVOUS PROTECTION MATERIALS
ATE229954T1 (en) * 1998-06-12 2003-01-15 Sod Conseils Rech Applic BETACARBOLINE COMPOUNDS
AR023171A1 (en) * 1999-03-26 2002-09-04 Cocensys Inc PIRAZOLES, IMIDAZOLES, OXAZOLES, TIAZOLES, AND PIRROLES REPLACED BY ARILO, AND THE USE OF THEMSELVES.
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof

Also Published As

Publication number Publication date
WO2002083656A3 (en) 2003-01-03
CA2443403C (en) 2011-09-20
AR036329A1 (en) 2004-09-01
CN1284777C (en) 2006-11-15
HUP0303799A2 (en) 2004-03-01
NO20034524L (en) 2003-10-29
CN1535267A (en) 2004-10-06
JP4422964B2 (en) 2010-03-03
EP1379514A2 (en) 2004-01-14
CZ20033054A3 (en) 2004-05-12
IL158121A0 (en) 2004-03-28
BR0208703A (en) 2006-02-21
HK1070055A1 (en) 2005-06-10
KR100865809B1 (en) 2008-10-28
NO20034524D0 (en) 2003-10-09
MXPA03009194A (en) 2004-02-17
RU2003132471A (en) 2005-01-27
IS6979A (en) 2003-10-08
DE60232959D1 (en) 2009-08-27
TWI248438B (en) 2006-02-01
NZ528645A (en) 2004-11-26
RU2288224C2 (en) 2006-11-27
EP1379514B1 (en) 2009-07-15
PL211939B1 (en) 2012-07-31
PL372297A1 (en) 2005-07-11
JP2004531526A (en) 2004-10-14
BRPI0208703B1 (en) 2017-12-12
CZ304550B6 (en) 2014-07-02
AU2002307980B2 (en) 2007-06-21
HUP0303799A3 (en) 2008-03-28
HU228192B1 (en) 2013-01-28
KR20030094333A (en) 2003-12-11
IS2724B (en) 2011-03-15
IL158121A (en) 2010-04-15
CA2443403A1 (en) 2002-10-24
WO2002083656A2 (en) 2002-10-24
NO326051B1 (en) 2008-09-08
ES2328467T3 (en) 2009-11-13

Similar Documents

Publication Publication Date Title
TW200509916A (en) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
BG106287A (en) Respiratory syncytial virus replication inhibitors
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
MY142094A (en) 5-membered heterocycles, preparation and application thereof as medicaments
DE602004028150D1 (en) AMINOPYRAZOL DERIVATIVES AS GSK-3 INHIBITORS
WO2008097538A8 (en) Therapeutic agents
GB0225475D0 (en) Therapeutic agents
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
GB0318447D0 (en) Therapeutic agents
NO20085271L (en) Muscarinic receptor agonists that are effective in treating pain, Alzheimer's disease and schizophrenia
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
MX2008013836A (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
NO20084853L (en) Compounds that are agonists of muscarinic receptors and which may be effective in the treatment of pain, Alzheimer's disease and / or schizophrenia
NO20063275L (en) Use of substituted 2-aminotetralins for the prophylaxis of Parkinson's disease
MY133572A (en) Gyrase inhibitors and uses thereof
MA27781A1 (en) 3-FLUORO-PIPERIDINES AS ANTAGONISTS OF NMDA / NR2B.
ATE409480T1 (en) PYRAZOLOA3,4-BUPYRIDINE-6-ONE AS GSK-3 INHIBITORS
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
ES2186550A1 (en) Derivatives of oxazolidinones as antibacterial agents
IL163413A (en) Oxa-and thiadiazoles, their use for the preparation of a medicament and process for their preparation
TNSN08447A1 (en) Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
BR0210392A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
MXPA04003611A (en) Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases.
EP4162937A4 (en) Pharmaceutical composition for preventing or treating parkinson's disease, comprising 2-(4-(1-hydroxypropane-2-yl)phenyl)isoindoline-1-one compound